人工智能不会自动加速临床试验

While there is optimism that AI can design better drug candidates, this alone cannot guarantee 'therapeutic abundance.' The history of drug development shows that even with strong preclinical models for conditions like osteoporosis, the high costs associated with moving a drug through trials deter investment. This phenomenon is frequently observed in the history of drug development, particularly for projects that require substantial funding and time. Investors tend to be cautious about high-risk drug development, indicating that advancements in AI alone cannot address the fundamental challenges of clinical trials.